Public market insider buying at Profound Medical (T:PRN)

Arthur Lee Rosenthal, a Director, acquired 6,500 Common Shares on a direct ownership basis at a price of $15.450USD on August 17th, 2021. This represents a $126,767 investment into the company's shares and an account share holdings change of greater than 100%.

Profound Medical is in the Advanced Medical Equipment & Technology Sub Industry Group under the Healthcare Sector.

Profound Medical Corp. is a commercial-stage medical device company. focused on customizable, incision-free therapies which combine real-time magnetic resonance imaging (MRI), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue. The Company's products include TULSA-PRO System and SONALLEVE. The TULSA-PRO is used to ablate benign or malignant prostate tissue in patients with a variety of prostate diseases. Prostate diseases include prostate cancer and benign prostatic hyperlasia (BPH). Prostate cancer is one of the common types of cancer affecting men. TULSA-PRO and SONALLEVE share the common technological concept of using MRI to enable visualization of the surgeon desired tissue in real time. Both products also use thermal ultrasound technology to heat and ablate tissue.